University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
Dallas, Texas, United States18 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07284849 | |
| Newborn Brain Assessment - CergenX Wave | Neonatal Encephalopathy; Neonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy); Neonatal Encephalopathy, Unspecified | Not yet recruiting | Not stated | 2026-10-05 | NCT07857070 | |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-09-25 | NCT05552222 | |
| A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05083169 | |
| Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Muscular Disorders, Atrophic, X-linked disease, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Not stated | 2026-09-24 | NCT06564974 | |
| Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT02704858 | |
| HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | EGFR Exon 19 Deletion; EGFR L858R; Nonsquamous Non-small Cell Lung Cancer | Active, not recruiting | Phase 3 | 2026-08-27 | NCT05338970 | |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, low grade glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2026-08-18 | NCT04485559 | |
| Domvanalimab and Zimberelimab in Advanced Liver Cancers | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, hepatocellular carcinoma, liver cancer, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-07-02 | NCT05724563 | |
| Understanding the Late Effects of Surviving a Pediatric Brain Tumor | Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, childhood malignant neoplasm, neoplasm, nervous system disorder | Active, not recruiting | Not stated | 2026-07-02 | NCT03208387 | |
| Social Media Concerns Related to Emotional Experiences in Naturalistic Settings (SCREENS) | Depression in Adolescence; Mental Health Issue; Social Media Addiction; Suicidal Ideation | Enrolling by invitation | Not stated | 2026-05-29 | NCT07278752 | |
| Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis | Disease Attributes, Hemic and Lymphatic Diseases, Lymphohistiocytosis, Hemophagocytic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, histiocytosis, lymphatic system disorder, non-Langerhans cell histiocytosis | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-24 | NCT04551131 | |
| Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | High-risk Large B-cell Lymphoma (LBCL) | Active, not recruiting | Phase 3 | 2026-04-15 | NCT05605899 | |
| A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Nutritional and Metabolic Diseases, Wilson disease, basal ganglia disorder, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, inborn metal metabolism disorder, inherited neurodegenerative disorder, liver disorder, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-30 | NCT04537377 | |
| Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Recruiting | Not stated | 2025-11-03 | NCT06683092 | |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 | 2025-09-22 | NCT05216432 | |
| A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer | Advanced Non Small Cell Lung Cancer; Advanced Urothelial Carcinoma | Active, not recruiting | Phase 2 | 2025-09-04 | NCT05318573 | |
| A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19 | Advanced Lymphoid Leukemia | Active, not recruiting | Phase 1 | 2025-04-11 | NCT02735083 |